SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Peter Karayiannis, Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis, Scientifica, 2012, 2012, 1

    CrossRef

  2. 2
    Sae Hwan Lee, Hong Soo Kim, In-Seon Byun, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Boo Sung Kim, Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy, Journal of Medical Virology, 2012, 84, 2
  3. 3
    David L. Veenstra, Sean D. Sullivan, Ming-Yang Lai, Chuan-Mo Lee, Chia-Ming Tsai, Kavita K. Patel, HBeAg-Negative Chronic Hepatitis B: Cost-Effectiveness of Peginterferon Alfa-2a Compared to Lamivudine in Taiwan, Value in Health, 2008, 11, 2
  4. 4
    J. Davis, Preventing hepatitis B virus reactivation following immunosuppressive therapy, Internal Medicine Journal, 2008, 38, 7
  5. 5
    Byung Chul Yoo, Ju Hyun Kim, Tae-Hun Kim, Kwang Cheol Koh, Soon-Ho Um, Young Soo Kim, Kwan Sik Lee, Byung Hoon Han, Chae Yoon Chon, Joon-Yeol Han, Soo Hyung Ryu, Haak Cheoul Kim, Kwan Soo Byun, Seong Gyu Hwang, Byung-Ik Kim, Mong Cho, Kwon Yoo, Heon-Ju Lee, Jae Seok Hwang, Yun Soo Kim, Young-Suk Lee, Sung-Kyu Choi, Youn-Jae Lee, Jin-Mo Yang, Joong-Won Park, Myung-Seok Lee, Dae-Ghon Kim, Young-Hwa Chung, Se-Hyun Cho, Jong-Young Choi, Young-Oh Kweon, Heon Young Lee, Sook-Hyang Jeong, Hee-Won Yoo, Hyo-Suk Lee, Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression, Hepatology, 2007, 46, 4
  6. 6
    Fabien Zoulim, Emerging drugs for hepatitis B, Expert Opinion on Emerging Drugs, 2007, 12, 2, 199

    CrossRef

  7. 7
    W. F. LEEMANS, M. J. TER BORG, R. A. DE MAN, Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2007, 26,
  8. 8
    Fabien Zoulim, Antiviral therapy of chronic hepatitis B, Antiviral Research, 2006, 71, 2-3, 206

    CrossRef

  9. 9
    Ching-Lung Lai, Daniel Shouval, Anna S. Lok, Ting-Tsung Chang, Hugo Cheinquer, Zachary Goodman, Deborah DeHertogh, Richard Wilber, Richard C. Zink, Anne Cross, Richard Colonno, Lori Fernandes, Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, 2006, 354, 10, 1011

    CrossRef

  10. 10
    Mariko Kobayashi, Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Tetsuya Hosaka, Hitomi Sezaki, Masahiro Kobayashi, Satomi Iwasaki, Junko Sato, Sachiyo Watahiki, Yuzo Miyakawa, Hiromitsu Kumada, Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C, Journal of Medical Virology, 2006, 78, 10
  11. 11
    Rosa Zampino, Aldo Marrone, Luigi Elio Adinolfi, Giuseppe Ruggiero, Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future, Expert Review of Clinical Immunology, 2006, 2, 6, 915

    CrossRef

  12. 12
    Hari S. Conjeevaram, Disease status and therapeutic end points in hepatitis B, Current Hepatitis Reports, 2005, 4, 1, 5

    CrossRef

  13. 13
    C. Yurdaydin, H. Bozkaya, H. Çetinkaya, T. Şahin, D. Karaoğuz, M. Törüner, Ö. Erkan, A. O. Heper, E. Erden, A. M. Bozdayi, Ö. Uzunalimoğlu, Lamivudine vs lamivudine and interferon combination treatment of HBeAg(−) chronic hepatitis B, Journal of Viral Hepatitis, 2005, 12, 3
  14. 14
    Cindy J. Lai, Norah A. Terrault, Antiviral therapy in patients with chronic hepatitis B and cirrhosis, Gastroenterology Clinics of North America, 2004, 33, 3, 629

    CrossRef

  15. 15
    Pilar León, Francisco Pozo, José M. Echevarría, Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain, Enfermedades Infecciosas y Microbiología Clínica, 2004, 22, 3, 133

    CrossRef

  16. 16
    Danny K.W. Soon, Stephen L. Lowe, Choo Hua Teng, Kwee Poo Yeo, James McGill, Stephen D. Wise, Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection, Journal of Hepatology, 2004, 41, 5, 852

    CrossRef

  17. 17
    Salvatore Madonia, Fabio Tinè, Giuseppe Malizia, Gandolfo Giannuoli, Maria Concetta Cascioni, Rosa Di Stefano, Sustained response after lamivudine treatment in HBe minus chronic hepatitis B, Journal of Hepatology, 2004, 40, 5, 870

    CrossRef

  18. 18
    L. D. Saravolatz, D. M. Asmuth, H. H. Nguyen, G. P. Melcher, S. H. Cohen, R. B. Pollard, Treatments for Hepatitis B, Clinical Infectious Diseases, 2004, 39, 9, 1353

    CrossRef

  19. 19
    M Lagget, M Rizzetto, Current pharmacotherapy for the treatment of chronic hepatitis B, Expert Opinion on Pharmacotherapy, 2003, 4, 10, 1821

    CrossRef

  20. 20
    Catherine Buffet, Hépatite chronique virale B, Revue Française des Laboratoires, 2003, 2003, 358, 31

    CrossRef

  21. 21
    Robert P. Perrillo, Hepatitis B: Treatment strategies for currently available drugs, Current Hepatitis Reports, 2003, 2, 2, 63

    CrossRef

  22. 22
    Hari S Conjeevaram, Anna Suk-Fong Lok, Management of chronic hepatitis B, Journal of Hepatology, 2003, 38, 90

    CrossRef

  23. 23
    Ioannis S Elefsiniotis, Ioannis Ketikoglou, Georgia Kafiri, Konstantinos D Pantazis, Antonios Moulakakis, Christos Mavrogiannis, Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment, European Journal of Gastroenterology & Hepatology, 2003, 15, 11, 1209

    CrossRef

  24. 24
    L. García Buey, J.A. Moreno Monteagudo, R. Moreno Otero, F. González Mateos, Tratamiento de las hepatitis víricas, Medicine - Programa de Formación Médica Continuada Acreditado, 2003, 8, 120, 6455

    CrossRef

  25. 25
    Mario Rizzetto, Alfredo Marzano, Marco Lagget, Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine, Journal of Hepatology, 2003, 39, 168

    CrossRef

  26. 26
    Guido Gerken, Christoph Jochum, Viral Infections and Treatment, 2003,

    CrossRef

  27. 27
    Ramachandra S. Hosmane, Antiviral Agents, Kirk-Othmer Encyclopedia of Chemical Technology,
  28. 28
    Peter Karayiannis, William F. Carman, Howard C. Thomas, Molecular Variants of the Precore, Core, and Core Promoter Regions of Hepatitis B Virus, and Their Clinical Significance,